From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ABBV stock is a Strong Buy.

The company is increasing its awareness campaign for cancer advocacy, including a partnership with the Chicago Cubs announced Friday, which could put thousands of dollars toward treating cancer.

"AbbVie Inc. (NYSE:ABBV) issued better than expected initial 2025 guidance and raised the long-term sales outlook for its two most important drugs.

Emrelis, an antibody drug conjugate developed by AbbVie, is now FDA approved for patients whose non-small cell lung cancer overexpresses the protein c-Met. The pharma company said this ADC is its ...

AbbVie is entering a collaboration and license option deal with ADARx Pharmaceuticals to develop a new type of RNA technology for disease areas like neuroscience, immunology and oncology. The deal ...

AbbVie shares rose Friday after the drugmaker's first-quarter results came in above analysts' expectations.

AbbVie (NYSE:ABBV) is scheduled to announce its earnings on Friday, April 25, 2025. Currently, the company holds a market capitalization of $307 billion. Over the past twelve months, AbbVie ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an analysis of ABBV stock now.

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the theft of trade secrets.

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...